A Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY2928057 in Hemodialysis Patients
Latest Information Update: 03 Oct 2021
At a glance
- Drugs LY 2928057 (Primary)
- Indications Anaemia
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Eli Lilly and Company (India) Pvt. Ltd
- 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
- 20 Nov 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 06 Aug 2015 Planned End Date changed from 1 Nov 2015 to 1 Oct 2015 as reported by ClinicalTrials.gov record.